Results 1 to 10 of about 385 (77)

A Case of Metastatic Renal Cell Carcinoma Successfully Treated With Deferred Cytoreductive Nephrectomy Following Lenvatinib Plus Pembrolizumab Combination Therapy [PDF]

IJU Case Reports, 2023
Introduction Combination therapy using immuno‐oncology drugs with tyrosine kinase inhibitors is increasingly important in the therapeutic strategy for metastatic renal cell carcinomas.
Hiroaki Sato, Takayuki Arai, Shinichi Sakamoto   +2 more
exaly   +3 more sources

Deliberation on Deferred Cytoreductive Nephrectomy and Postoperative Treatment for Advanced Renal Cell Carcinoma: A Case Report [PDF]

Case Reports in Oncology, 2022
In a rare case, free from systemic therapy, deferred cytoreductive nephrectomy was implemented in treating an advanced renal cell carcinoma with liver, lung, and splenic colon metastases.
Atsushi Kohyama, Yoshihide Kawasaki, Hiromichi Katayama   +2 more
exaly   +4 more sources

Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy Be Withdrawn in Patients With No Evidence of Disease? [PDF]

European Urology Open Science, 2023
Background: Upfront cytoreductive nephrectomy (CN) is no longer the standard of care for patients with metastastic renal cell carcinoma (mRCC) with intermediate or poor prognosis according to the International mRCC Database Consortium categories ...
Johannes V van Thienen, Ekaterini Boleti
exaly   +4 more sources

The Impact of Deferred Cytoreductive Nephrectomy on Survival in Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis [PDF]

Asian Journal of Urology
Objective: Stage IV renal cell carcinoma (RCC) is associated with a significant decrease in survival rates. Cytoreductive nephrectomy (CN) is one of the treatments for stage IV RCC.
Syah Mirsya Warli, Fauriski Febrian Prapiska, Mohammad Taufiq Alamsyah   +2 more
exaly   +4 more sources

Multicenter Randomized Trial of Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma Receiving Checkpoint Inhibitors: The NORDIC-SUN-Trial [PDF]

BMC Cancer
Background Primary tumor removal by cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma patients has been investigated in the context of various treatment regimens. Two randomized controlled trials investigated the role and timing of
Johanne Ahrenfeldt, Börje Ljungberg, Frede Donskov   +2 more
exaly   +3 more sources

Deferred Cytoreductive Nephrectomy With Partial Hepatectomy for Giant Renal Cell Carcinoma of the Right Kidney With Extensive Hepatic Invasion: A Case Report in the Era of Systemic Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors [PDF]

IJU Case Reports
Introduction Deferred cytoreductive nephrectomy may improve the prognosis of patients with metastatic renal cell carcinoma (RCC). However, reports of combined hepatic resection for RCC with liver invasion are limited, and treatment strategies remain ...
Yuki Hiroshi, Takamitsu Inoue, Takuya Minagawa, Masaki Takahashi, Akinobu Katami, Mizuki Onozawa, Masahiro Shinoda, Osamu Itano, Jun Miyazaki   +8 more
doaj   +2 more sources

The role of delayed cytoreductive nephrectomy following axitinib–toripalimab for the mRCC patient in current immunotherapy era: a case report and literature review [PDF]

Frontiers in Immunology
The global incidence of renal cell carcinoma (RCC) has shown a significant upward trend in recent years, with growing health inequities related to its incidence. RCC remains the most lethal urological cancer.
Quan Zhou, Quan Zhou, Junlong Wang, Ma WenJing, Ye ZeLin, Ye ZeLin, Jiasheng Yan, Xiaodong Jin, Xiaodong Jin   +8 more
doaj   +2 more sources

The ITALIC-RCC: A Randomized Trial on Clinical and Humoral Impact of Primary Tumor Ablation by Surgery or Radiotherapy in Metastatic Renal Cell Carcinoma Treated with Checkpoint Inhibitors [PDF]

European Urology Open Science
Background: Immunotherapy-based combinations have improved overall survival (OS) in metastatic renal cell carcinoma (mRCC), but recent evidence suggests a therapeutic plateau, underscoring the need for more personalized strategies.
Roberto Iacovelli, Chiara Ciccarese, Daniela Arduini, Luca Tagliaferri, Andrea Minervini, Giuseppe Simone, Vincenzo Ficarra, Camillo Porta, Fabio Calabrò, Paolo Zucali, Paola Troisi, Giulio Francolini, Alessio Giuseppe Morganti, Ciro Franzese, Barbara Alicja Jereczek-Fossa, Bernardo Cesare Maria Rocco   +15 more
doaj   +2 more sources

Case Report: Locally advanced clear cell renal cell carcinoma with pathological complete response following nephrectomy and thrombectomy after nivolumab and cabozantinib treatment [PDF]

Frontiers in Oncology
The recent introduction of systemic anticancer therapies (SACT) and immune checkpoint inhibitors in cancer management has led to reports on the usefulness of deferred cytoreductive nephrectomy (dCN) following vascular endothelial growth factor receptor ...
Hayato Yoshioka, Hiroyuki Kitano, Kohei Kobatake, Yohei Sekino, Akira Ishikawa, Keisuke Goto, Akihiro Goriki, Keisuke Hieda, Kouji Arihiro, Nobuyuki Hinata   +9 more
doaj   +2 more sources

Case Report: complete response to preoperative ipilimumab and nivolumab combination therapy in advanced papillary renal cell carcinoma with inferior vena cava tumor thrombus and multiple metastases [PDF]

Frontiers in Oncology
IntroductionCombination therapy comprising ipilimumab and nivolumab is a safe and effective treatment for advanced renal cell carcinoma (RCC). However, its use in papillary RCC (pRCC) with an inferior vena cava (IVC) tumor thrombus extending to the right
Chika Nagahisa, Kazuhiko Yoshida, Shuhei Nozaki, Shinsuke Mizoguchi, Hironori Fukuda, Yuki Kobari, Junpei Iizuka, Yoji Nagashima, Hideki Ishida, Toshio Takagi   +9 more
doaj   +2 more sources